Vericel Reports Third Quarter 2021 Financial Results
Vericel Corporation (NASDAQ: VCEL) reported third quarter 2021 net revenue of $34.5 million, a 7% increase from $32.3 million in Q3 2020. Year-to-date revenue rose 38% to $108.6 million. Notably, MACI revenue was $23.9 million, and Epicel revenue was $9.8 million. The company faced a net loss of $4.9 million or $0.11 per share, contrasting with net income of $3.6 million in Q3 2020. Gross margin decreased to 64%, down from 70% the previous year. The company adjusted its full-year revenue guidance to reflect a projected increase of 27%-30%.
- Year-to-date revenue increased 38% to $108.6 million.
- MACI revenue grew to $74.2 million YTD.
- Epicel net revenue saw 48% growth in Q3 2021 compared to Q3 2020.
- Operating cash flow generated was $3.6 million.
- Company reported $119 million in cash and investments, no debt.
- Net loss of $4.9 million, compared to net income of $3.6 million in Q3 2020.
- Gross margin decreased to 64% from 70% in Q3 2020.
- Operating expenses rose to $27.1 million from $19.0 million in Q3 2020.
Third Quarter Total Net Revenue of
Year-To-Date 2021 Revenue Increased
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2021.
Third Quarter 2021 Financial Highlights
- Total net revenue of
$34.5 million , compared to$32.3 million in the third quarter of 2020 - MACI® net revenue of
$23.9 million , Epicel® net revenue of$9.8 million , and NexoBrid® revenue of$0.8 million related to the U.S. Biomedical Advanced Research and Development Authority (BARDA) procurement for emergency response preparedness - Gross margin of
64% , compared to70% in the third quarter of 2020 - Net loss of
$4.9 million , or$0.11 per share, compared to net income of$3.6 million , or$0.08 per share, in the third quarter of 2020 - Non-GAAP adjusted EBITDA of
$4.3 million , compared to$6.7 million in the third quarter of 2020 - Operating cash flow of
$3.6 million - As of September 30, 2021, the Company had approximately
$119 million in cash and investments, compared to approximately$100 million as of December 31, 2020, and no debt
Year-to-Date 2021 Financial Highlights
- Total net revenue of
$108.6 million , compared to$79.0 million in 2020 - MACI net revenue of
$74.2 million , Epicel net revenue of$31.8 million , and NexoBrid revenue of$2.6 million related to BARDA procurement for emergency response preparedness - Gross margin of
66% , compared to64% for the same period in 2020 - Net loss of
$12.0 million , or$0.26 per share, compared to net loss of$9.4 million , or$0.21 per share, for the same period in 2020 - Non-GAAP adjusted EBITDA of
$16.7 million , compared to$2.5 million for the same period in 2020 - Operating cash flow of
$18.5 million
Business Highlights and Updates
- Growth in surgeons taking MACI biopsies in 2021 is on track to exceed
20% and growth in total MACI biopsies is expected to exceed30% , compared to 2020 - Epicel net revenue growth of
48% compared to the third quarter of 2020 and the fourth straight quarter with Epicel revenue over$9 million - Growth of over
30% in Epicel biopsies and treated patients through the first nine months of 2021 compared to the same period in 2020 - Following a Type A meeting with the FDA, the Company anticipates resubmission of the NexoBrid Biologics License Application in mid-2022
- Expanded executive leadership team and appointed Patrick Fowler as Vericel’s Senior Vice President of Corporate Development and Strategy
“Despite additional COVID-19 disruptions in the third quarter, the Company delivered solid commercial and operational results and continued to generate top-line revenue growth, positive adjusted EBITDA and operating cash flow for the quarter,” said Nick Colangelo, President and CEO of Vericel. “Based on the strength of the underlying growth drivers for MACI and Epicel, we are poised to deliver strong growth for both of our franchises this year with Epicel growth of approximately
Full-Year 2021 Financial Guidance Update
- Total net revenue now expected to increase
27% -30% to approximately$158 -$161 million - Gross margin now expected to be approximately
70% - Adjusted EBITDA margin now expected to be approximately
22% - Estimated operating expenses of approximately
$114 million
Third Quarter 2021 Results
Total net revenue for the quarter ended September 30, 2021 increased
Gross profit for the quarter ended September 30, 2021 was
Total operating expenses for the quarter ended September 30, 2021 were
Net loss for the quarter ended September 30, 2021 was
Non-GAAP adjusted EBITDA for the quarter ended September 30, 2021 was
As of September 30, 2021, the Company had approximately
Conference Call Information
Today’s conference call will be available live at 8:30am Eastern Time and can be accessed through the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. A slide presentation with highlights from today’s conference call will be available on the webcast and in the Investor Relations section of the Vericel website. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software, if necessary. To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation’s second quarter 2021 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until November 9, 2022. A replay of the call will also be available until 11:30am (EDT) on November 13, 2021 by calling (855) 859-2056, or from outside the U.S. by calling (404) 537-3406. The conference ID is 2998214.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The Company markets two cell therapy products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to
GAAP v. Non-GAAP Measures
Vericel’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. Vericel has provided in this release certain financial information that has not been prepared in accordance with GAAP. Vericel’s management believes that the non-GAAP adjusted EBITDA described in the release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Vericel’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Vericel’s industry. However, the non-GAAP financial measures that Vericel uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. (MediWound) and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.
Forward-Looking Statements
Vericel cautions you that all statements other than statements of historical fact included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.
Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI and Epicel, growth in profit, gross margins and operating margins, the ability to achieve or sustain profitability, contributions to adjusted EBITDA, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing of the resubmission to the Food & Drug Administration (FDA) of a Biologics License Application (BLA) for NexoBrid seeking approval for the treatment of severe burns in the United States following MediWound’s receipt of a complete response on June 28, 2021, timing or likelihood of approval by the FDA of the NexoBrid BLA resubmission, the estimate of the commercial growth potential of our products and product candidates, availability of funding from BARDA under its agreement with MediWound for use in connection with NexoBrid development activities, competitive developments, changes in third-party coverage and reimbursement, our ability to supply or meet customer demand for our products, and the wide-ranging impacts of the COVID-19 pandemic on our business or the economy generally.
With respect to COVID-19, we are currently unable to predict whether the current spread of the COVID-19 “Delta” variant or a future resurgence of COVID-19 infections that may limit the effectiveness of approved vaccines will result in future restrictions on the performance of elective surgical procedures or affect the availability of physicians and/or their treatment prioritizations, cause healthcare facility staffing shortages, effect the willingness or ability of patients to seek treatment, or heighten the impact of the outbreak on the overall healthcare infrastructure. Other disruptions or potential disruptions include restrictions on the ability of Company personnel to travel and access customers for training, promotion and case support, delays in product development efforts, and additional government-imposed quarantines and requirements to “shelter at home” or other incremental mitigation efforts or initiatives that may impact our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products. With respect to NexoBrid, the COVID-19 pandemic may impact the FDA’s response times to future regulatory submissions, its ability to monitor our clinical trials, and/or conduct necessary reviews or inspections of manufacturing facilities involved in the production of NexoBrid, any or all of which may result in timelines being materially delayed, which could affect the development and ultimate commercialization of NexoBrid. The total impact of these disruptions could have a material impact on the Company’s financial condition, cash flows and results of operations.
These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (SEC) on February 24, 2021, Vericel’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 9, 2021, and in other filings with the SEC. These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
VERICEL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, amounts in thousands)
| September 30, | December 31, | |||||||||
| 2021 | 2020 | |||||||||
| ASSETS | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 54,553 | $ | 33,620 | ||||||
| Short-term investments | 43,738 | 42,187 | ||||||||
| Accounts receivable (net of allowance for doubtful accounts of | 28,910 | 34,504 | ||||||||
| Inventory | 13,059 | 9,356 | ||||||||
| Other current assets | 4,686 | 3,893 | ||||||||
| Total current assets | 144,946 | 123,560 | ||||||||
| Property and equipment, net | 11,819 | 7,633 | ||||||||
| Restricted cash | 211 | 211 | ||||||||
| Right-of-use assets | 46,713 | 50,105 | ||||||||
| Long-term investments | 20,235 | 24,099 | ||||||||
| Other long-term assets | 219 | — | ||||||||
| Total assets | $ | 224,143 | $ | 205,608 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable | $ | 5,575 | $ | 6,755 | ||||||
| Accrued expenses | 10,932 | 11,293 | ||||||||
| Current portion of operating lease liabilities | 2,280 | 4,394 | ||||||||
| Other liabilities | 41 | 41 | ||||||||
| Total current liabilities | 18,828 | 22,483 | ||||||||
| Operating lease liabilities | 48,493 | 48,789 | ||||||||
| Other long-term liabilities | 42 | 76 | ||||||||
| Total liabilities | $ | 67,363 | $ | 71,348 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||||
| Shareholders’ equity: | ||||||||||
| Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 46,767 and 45,804, respectively | 544,624 | 510,061 | ||||||||
| Accumulated other comprehensive income (loss) | (23 | ) | 14 | |||||||
| Accumulated deficit | (387,821 | ) | (375,815 | ) | ||||||
| Total shareholders’ equity | 156,780 | 134,260 | ||||||||
| Total liabilities and shareholders’ equity | $ | 224,143 | $ | 205,608 | ||||||
VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||||||
| Product sales, net | $ | 33,718 | $ | 31,020 | $ | 106,025 | $ | 77,712 | ||||||||||||
| Other revenue | 788 | 1,238 | 2,568 | 1,238 | ||||||||||||||||
| Total revenue | 34,506 | 32,258 | 108,593 | 78,950 | ||||||||||||||||
| Cost of product sales | 12,408 | 9,787 | 36,600 | 28,369 | ||||||||||||||||
| Gross profit | 22,098 | 22,471 | 71,993 | 50,581 | ||||||||||||||||
| Research and development | 4,284 | 2,913 | 12,363 | 9,902 | ||||||||||||||||
| Selling, general and administrative | 22,775 | 16,041 | 71,625 | 50,596 | ||||||||||||||||
| Total operating expenses | 27,059 | 18,954 | 83,988 | 60,498 | ||||||||||||||||
| Income (loss) from operations | (4,961 | ) | 3,517 | (11,995 | ) | (9,917 | ) | |||||||||||||
| Other income (expense): | ||||||||||||||||||||
| Interest income | 44 | 121 | 163 | 574 | ||||||||||||||||
| Interest expense | (1 | ) | (2 | ) | (3 | ) | (5 | ) | ||||||||||||
| Other income (expense) | (13 | ) | (18 | ) | 45 | (8 | ) | |||||||||||||
| Total other income | 30 | 101 | 205 | 561 | ||||||||||||||||
| Income (loss) before tax expense | (4,931 | ) | 3,618 | (11,790 | ) | (9,356 | ) | |||||||||||||
| Tax expense | — | — | (215 | ) | — | |||||||||||||||
| Net income (loss) | $ | (4,931 | ) | $ | 3,618 | $ | (12,006 | ) | $ | (9,356 | ) | |||||||||
| Net income (loss) per common share (Basic and Diluted) | $ | (0.11 | ) | $ | 0.08 | $ | (0.26 | ) | $ | (0.21 | ) | |||||||||
| Weighted average common shares outstanding (Basic) | 46,669 | 45,272 | 46,355 | 45,112 | ||||||||||||||||
| Weighted average common shares outstanding (Diluted) | 46,669 | 47,314 | 46,355 | 45,112 | ||||||||||||||||
| RECONCILIATION OF REPORTED NET INCOME (LOSS) (GAAP) | |||||||||||||||||||
| TO ADJUSTED EBITDA (NON-GAAP MEASURE) - UNAUDITED | |||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||
| (In thousands) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||
| Net income (loss) | $ | (4,931 | ) | $ | 3,618 | $ | (12,006 | ) | $ | (9,356 | ) | ||||||||
| Stock-based compensation expense | 8,596 | 2,675 | 26,481 | 10,819 | |||||||||||||||
| Depreciation and amortization | 679 | 570 | 2,185 | 1,649 | |||||||||||||||
| Net interest income | (43 | ) | (119 | ) | (160 | ) | (569 | ) | |||||||||||
| Income tax expense | — | — | 215 | — | |||||||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 4,301 | $ | 6,744 | $ | 16,715 | $ | 2,543 | |||||||||||
FAQ
What were Vericel's total net revenues for the third quarter of 2021?
How much did Vericel's revenue increase year-to-date in 2021?
What is the net loss reported by Vericel for Q3 2021?
What is the projected revenue increase for Vericel for full-year 2021?
What was the gross margin reported by Vericel for Q3 2021?
